ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that
targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate
the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of
ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the
phase Ib/II starting dose for ACE1702.